144 103

Cited 48 times in

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

DC FieldValueLanguage
dc.contributor.author안상훈-
dc.date.accessioned2016-02-04T11:57:07Z-
dc.date.available2016-02-04T11:57:07Z-
dc.date.issued2015-
dc.identifier.issn0741-238X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/141562-
dc.description.abstractINTRODUCTION: Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor) is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV + ASV is affected by DCV resistance-associated polymorphisms (RAPs) in HCV NS5A. The prevalence and influence of these RAPs on 12-week sustained virologic response (SVR12) to DCV + ASV was evaluated in Asian and non-Asian patients. METHODS: Data were pooled from 5 national and international studies of patients with HCV genotype 1b (GT-1b) receiving DCV + ASV at their recommended doses. Baseline NS5A RAPs and their effect on SVR12 were assessed overall, in older (≥65 years) patients, patients with cirrhosis, and in patients stratified by baseline HCV RNA or prior treatment experience with interferon-based therapy. RESULTS: Baseline NS5A sequences were available from 988 patients (374 Japanese; 125 Korean/Taiwanese; 489 from non-Asian countries), 979 of whom were assessed for SVR12. Pretreatment NS5A-L31F/I/M/V and/or NS5A-Y93H polymorphisms were present in 18% of Japanese and 12-13% of non-Japanese patients; these RAPs reduced SVR12 by 54.9% overall (93.9% [787/838] SVR12 when absent, 39.0% [55/141] SVR12 when present), with comparable reductions observed in Asians and non-Asians and across all categories of treatment experience, age, and cirrhosis. RAP-associated SVR12 rates declined with increasing baseline HCV RNA (SVR12 with RAPs: 64.7% [11/17] at 5-6 log10 IU/mL, 29.8% [14/47] at 7-8 log10). Without baseline RAPs, very high SVR12 rates (92-100%) were observed in older patients and patients with cirrhosis irrespective of national origin, with similarly high rates observed among treatment-naïve and interferon-experienced patients and those with high baseline HCV RNA. CONCLUSIONS: Following DCV + ASV treatment, the SVR12 rates in GT-1b patients without baseline NS5A-L31F/I/M/V and/or NS5A-Y93H polymorphisms were very high (approximately 90-100%), irrespective of age, cirrhosis, prior interferon treatment, or baseline HCV RNA. FUNDING: Bristol-Myers Squibb.-
dc.description.statementOfResponsibilityopen-
dc.format.extent637~649-
dc.relation.isPartOfAdvances in Therapy-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntiviral Agents/administration & dosage-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHAsian Continental Ancestry Group-
dc.subject.MESHDrug Resistance, Viral/genetics-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHGenotype-
dc.subject.MESHHepacivirus/genetics*-
dc.subject.MESHHepatitis C, Chronic/complications-
dc.subject.MESHHepatitis C, Chronic/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHImidazoles/administration & dosage-
dc.subject.MESHImidazoles/therapeutic use*-
dc.subject.MESHIsoquinolines/administration & dosage-
dc.subject.MESHIsoquinolines/therapeutic use*-
dc.subject.MESHJapan-
dc.subject.MESHLiver Cirrhosis/drug therapy*-
dc.subject.MESHLiver Cirrhosis/etiology-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPhosphoproteins/genetics-
dc.subject.MESHPolymorphism, Genetic-
dc.subject.MESHSulfonamides/administration & dosage-
dc.subject.MESHSulfonamides/therapeutic use*-
dc.subject.MESHViral Nonstructural Proteins/genetics-
dc.subject.MESHYoung Adult-
dc.titleHigh Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorFiona McPhee-
dc.contributor.googleauthorYoshiyuki Suzuki-
dc.contributor.googleauthorJoji Toyota-
dc.contributor.googleauthorYoshiyasu Karino-
dc.contributor.googleauthorKasuaki Chayama-
dc.contributor.googleauthorYoshiiku Kawakami-
dc.contributor.googleauthorMin Lung Yu-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorHiroki Ishikawa-
dc.contributor.googleauthorRafia Bhore-
dc.contributor.googleauthorNannan Zhou-
dc.contributor.googleauthorDennis Hernandez-
dc.contributor.googleauthorPatricia Mendez-
dc.contributor.googleauthorHiromitsu Kumada-
dc.identifier.doi10.1007/s12325-015-0221-5-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02226-
dc.relation.journalcodeJ00048-
dc.identifier.pmid26155891-
dc.subject.keywordAsunaprevir-
dc.subject.keywordDaclatasvir-
dc.subject.keywordDrug resistance-
dc.subject.keywordInfectious diseases-
dc.subject.keywordViral hepatitis-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.rights.accessRightsfree-
dc.citation.volume32-
dc.citation.number7-
dc.citation.startPage637-
dc.citation.endPage649-
dc.identifier.bibliographicCitationAdvances in Therapy, Vol.32(7) : 637-649, 2015-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.